Zhejiang Wolwo Bio-Pharmaceutical (300357) Stock Overview
A biopharmaceutical company, engages in the research, development, production, and sale of pharmaceutical products for the diagnosis and treatment of allergic diseases in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
300357 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥30.95 |
| 52 Week High | CN¥32.47 |
| 52 Week Low | CN¥16.32 |
| Beta | 0.83 |
| 1 Month Change | 18.13% |
| 3 Month Change | 54.13% |
| 1 Year Change | 83.35% |
| 3 Year Change | -33.12% |
| 5 Year Change | -48.66% |
| Change since IPO | 450.41% |
Recent News & Updates
Recent updates
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357) Shares Could Be 36% Below Their Intrinsic Value Estimate
Feb 24
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s (SZSE:300357) Price Is Out Of Tune With Earnings
Jan 19Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Has A Pretty Healthy Balance Sheet
Jan 01Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s (SZSE:300357) P/E Is Still On The Mark Following 39% Share Price Bounce
Sep 30These 4 Measures Indicate That Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Is Using Debt Reasonably Well
Sep 26Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Has Announced That Its Dividend Will Be Reduced To CN¥0.185
Jun 30Investor Optimism Abounds Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357) But Growth Is Lacking
May 27Calculating The Fair Value Of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357)
May 07Is Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) A Risky Investment?
Mar 22Shareholder Returns
| 300357 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 13.9% | 1.3% | 4.1% |
| 1Y | 83.4% | 46.2% | 51.9% |
Return vs Industry: 300357 exceeded the CN Pharmaceuticals industry which returned 46.2% over the past year.
Return vs Market: 300357 exceeded the CN Market which returned 51.9% over the past year.
Price Volatility
| 300357 volatility | |
|---|---|
| 300357 Average Weekly Movement | 6.3% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in CN Market | 8.6% |
| 10% least volatile stocks in CN Market | 2.8% |
Stable Share Price: 300357 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300357's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 1,679 | Jianming He | www.wolwobiotech.com |
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceutical products for the diagnosis and treatment of allergic diseases in China and internationally. The company offers Changdi, a dust mine drops; Changhao, an artemisia annua pollen allergen sublingual drops; Changdian, a dust mite skin prick diagnostic kit; and Changdian II, a house dust mite skin prick diagnosis kit. It also involved in the research and development of stem cells and medical artificial intelligence solutions.
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Fundamentals Summary
| 300357 fundamental statistics | |
|---|---|
| Market cap | CN¥16.20b |
| Earnings (TTM) | CN¥345.60m |
| Revenue (TTM) | CN¥980.37m |
Is 300357 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300357 income statement (TTM) | |
|---|---|
| Revenue | CN¥980.37m |
| Cost of Revenue | CN¥46.84m |
| Gross Profit | CN¥933.53m |
| Other Expenses | CN¥587.93m |
| Earnings | CN¥345.60m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.66 |
| Gross Margin | 95.22% |
| Net Profit Margin | 35.25% |
| Debt/Equity Ratio | 0.2% |
How did 300357 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/27 22:38 |
| End of Day Share Price | 2025/08/27 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kai Wang | Citic Securities Co., Ltd. |
| Xiao Wei Lin | Everbright Securities Co. Ltd. |
| Yaming Liu | Founder Securities Co., Ltd. |